State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop

Main Article Content

Erwin van Vliet, Jochen Kühnl, Carsten Goebel, Silvia Martinozzi-Teissier, Nathalie Alépée, Takao Ashikaga, Brunhilde Blömeke, Aurélia Del Bufalo, Magalie Cluzel, Emanuela Corsini, Nathalie Delrue, Bertrand Desprez, Nichola Gellatly, Christoph Giese, Laura Gribaldo, Sebastian Hoffmann, Martina Klaric , Bernard Maillere, Dean Naisbitt, Marc Pallardy, Marc Vocanson, Dirk Petersohn
[show affiliations]


Significant progress has been made in the development and validation of non-animal test methods for skin sensitization assessment. At present, three of the four key events of the adverse outcome pathway (AOP) are assessable by OECD-accepted in vitro methods. The fourth key event describes the immunological response in the draining lymph node where activated den­dritic cells present major histocompatibility complex-bound chemically modified peptides to naïve T cells, thereby priming the proliferation of antigen-specific T cells. Despite substantial efforts, modelling and assessing this adaptive immune response to sensitizers with in vitro T cell assays still represents a challenge. The Cosmetics Europe Skin Tolerance Task Force organized a workshop, bringing together academic researchers, method developers, industry representatives and regulatory stakeholders to review the scientific status of T cell-based assays, foster a mutual scientific understanding and conceive new options to assess T cell activation. Participants agreed that current T cell assays have come a long way in predicting immunogenicity, but that further investment and collaboration is required to simplify assays, optimize their sensitivity, better define human donor-to-donor variability and evaluate their value to predict sensitizer potency. Furthermore, the potential role of T cell assays in AOP-based testing strategies and subsequent safety assessment concepts for cosmetic ingredients was discussed. It was agreed that it is currently difficult to anticipate uses of T cell assay data for safety assessment and concluded that experience from case studies on real-life risk assessment scenarios is needed to further consider the usefulness of assessing the fourth AOP key event.

Article Details

How to Cite
van Vliet, E. (2018) “State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop”, ALTEX - Alternatives to animal experimentation, 35(2), pp. 179–192. doi: 10.14573/altex.1709011.

Most read articles by the same author(s)

<< < 1 2 3 4 5